Cuong-Dung Do, MD
Ophthalmology · Westminster, CANPI 1477574200
Payments from drug & device makers
Across 799 payments — averaging $28.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Eyevance Pharmaceuticals LLC$3K
- Aerie Pharmaceuticals, Inc.$2K
- Alcon$2K
- Bausch & Lomb Americas Inc.$2K
- Sun Pharmaceutical Industries Inc.$2K
- plus $8K from 24 others
What the payments were for
- Consulting fees$3,47015%
- Food & beverage$19,25684%
- Education$800%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 138 | $4,048 |
| Eyevance Pharmaceuticals LLC | 37 | $2,759 |
| Aerie Pharmaceuticals, Inc. | 71 | $2,150 |
| Alcon | 76 | $2,072 |
| Bausch & Lomb Americas Inc. | 100 | $2,043 |
| Sun Pharmaceutical Industries Inc. | 44 | $2,016 |
| Oyster Point Pharma, Inc. | 44 | $1,446 |
| Mallinckrodt Hospital Products Inc. | 56 | $1,036 |
| Novartis | 76 | $1,028 |
| Amgen(2 entities) | 44 | $941 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $569 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $544 |
| Kala Pharmaceuticals, Inc. | 23 | $403 |
| ANI Pharmaceuticals, Inc. | 11 | $310 |
| Dompe US, Inc. | 4 | $199 |
| Shire North American Group Inc | 9 | $188 |
| Tarsus Pharmaceuticals, Inc. | 7 | $181 |
| Sight Sciences, Inc. | 3 | $158 |
| Ivantis, Inc | 2 | $152 |
| Rxsight Inc | 2 | $136 |
| Ocular Therapeutix, Inc. | 6 | $89 |
| Biogen | 1 | $85 |
| Apellis Pharmaceuticals, Inc. | 2 | $65 |
| Thea Pharma Inc. | 3 | $65 |
| Glaukos Corporation | 2 | $38 |
| Akorn Operating Company LLC | 1 | $22 |
| Akorn, Inc. | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Santen Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flarex$1,376
- Rocklatan$1,071
- Rhopressa$945
- CEQUA$850
- TYRVAYA$793
- Tobradex ST$733
- VYZULTA$676
- XEN GLAUCOMA TREATMENT SYSTEM$629
- LOTEMAX SM$354
- ACTHAR$270
- Tecnis IOL$247
- TEPEZZA$246
- XELPROS$240
- XIIDRA$236
- enVista MX60 IOL$217
- Hydrus Microstent$149
- Hydrus$136
- Tecnis Simplicity$135
- ACTIVEFOCUS$127
- AcrySof$127
How this compares
$22,825 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 1,650 | $1,119,486 |
| VyzultaLatanoprostene Bunod | 3,865 | $1,024,907 |
| XiidraLifitegrast | 1,209 | $887,320 |
| LumiganBimatoprost | 2,973 | $769,273 |
| TyrvayaVarenicline Tartrate | 759 | $501,609 |
| MieboPerfluorohexyloctane/Pf | 602 | $467,697 |
| Cyclosporine | 1,362 | $427,425 |
| AlrexLoteprednol Etabonate | 747 | $226,670 |
| RhopressaNetarsudil Mesylate | 610 | $204,591 |
| CequaCyclosporine | 294 | $172,758 |
| RocklatanNetarsudil Mesylat/Latanoprost | 414 | $145,001 |
| CombiganBrimonidine Tartrate/Timolol | 632 | $133,108 |
| ZerviateCetirizine Hcl | 301 | $132,760 |
| AzoptBrinzolamide | 185 | $67,353 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 319 | $64,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo, Zirgan | $2,043 | $2,385,4745,688 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $4,048 | $2,056,7655,407 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,446 | $501,609759 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $2,150 | $349,5911,024 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Lotemax Sm, Lotemax, Loteprednol Etabonate | $569 | $294,4091,017 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $2,016 | $172,758294 claims |
| Eyevance Pharmaceuticals LLCZerviate | $2,759 | $132,760301 claims |
| AlconAzopt, Simbrinza | $2,072 | $132,039504 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $403 | $59,227120 claims |
| Akorn, Inc.Zioptan | $20 | $6,34920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Westminster
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.